Where does ImaginAb, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), ImaginAb, Inc. ranks #26,526 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does ImaginAb, Inc. hold?

ImaginAb, Inc. holds 10 US utility patents granted between 2018 and 2025, spanning 5 technology areas.

What is ImaginAb, Inc.'s Innovation Score?

ImaginAb, Inc. has an Innovation Score of 30.8 out of 100 (35th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does ImaginAb, Inc. focus on?

ImaginAb, Inc.'s top technology area is C07K (Peptides) with 8 patents. Grants appear in 5 CPC subclasses total.

Is ImaginAb, Inc.'s patent grant rate increasing or decreasing?

ImaginAb, Inc.'s recent grant velocity is +25% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for ImaginAb, Inc.'s patents?

ImaginAb, Inc.'s patents average 20.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the ImaginAb, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

ImaginAb, Inc.

USPTO PatentsView assignee record - 10 granted patents across 5 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Imaginab ranks #26,526 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 5 technology areas.

#26,526
of 49,997 US assignees by volume: 35th percentile
by Innovation Score (30.8/100): 20.6
avg claims per patent: +25%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26526 · US Corporation #26,526 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,526/49,997
PHOTO-FINISH Icon Genetics
CPC-NARROW C07K · 5 areas
INNOV-THIN 30.8/100
CLAIMS-DENSE 20.6 claims/avg
TYPE-USCORP US Corporation
VEL-UP +25% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Icon Genetics GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
ImaginAb · this assignee

31
3D Lighting… · lowest

7

What this shows Imaginab's Innovation Score is 30.8/100 (35th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Imaginab's grants concentrate

ImaginAb, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 80% of grants classified under C07K (Peptides). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2018. By volume, Imaginab sits between Icon Genetics GmbH and Inca Digital Printers Limited.

Imaginab's three-year grant acceleration

ImaginAb, Inc. shows 2 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Icon Genetics

10
Icuemotion

10
Identy

10
Illumigyn

10
Immersive Robotic…

10
Impel Neuropharma

10
Impel Pharmaceuti…

10
Inca Digital Prin…

10
Imaginab ◀

10

What this shows ImaginAb holds 10 patents at rank #26,571, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near ImaginAb

By rank, the assignees closest to #26,571 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in ImaginAb's primary technology class.

Imaginab's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 35th percentile higher than 35% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

ImaginAb, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	10.0%
2019	3	30.0%
2021	3	30.0%
2022	2	20.0%
2025partial year	1	10.0%

Which technologies does ImaginAb, Inc. patent most?

C07K - Peptides 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

Top 5 of 5 technology areas

Where it ranks

Overall rank by patents

#26,526

of 49,997 tracked assignees

Innovation Score

30.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

ImaginAb, Inc.'s patent record in context - here's where to go next.

ImaginAb, Inc.'s lead technology class is C07K (Peptides), 80% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #26,526 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare ImaginAb, Inc. against Icon Genetics GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.